Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC)
I'm PortAI, I can summarize articles.
Craig-Hallum's Chase Knickerbocker has reaffirmed a Buy rating on Diamedica Therapeutics, with the stock closing at $8.48. Knickerbocker, a top 100 analyst with a 35.7% average return, focuses on the Healthcare sector. The analyst consensus for Diamedica is a Strong Buy, with an average price target of $17.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments